$11.59
0.70% today
NYSE, Feb 05, 04:20 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$11.51
-0.41 3.44% 1M
-0.34 2.87% 6M
-0.60 4.95% YTD
-4.39 27.61% 1Y
-13.46 53.90% 3Y
-20.15 63.65% 5Y
-24.49 68.03% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.21 1.79%
ISIN
US28414H1032
Symbol
ELAN

Key metrics

Market capitalization $5.69b
Enterprise Value $9.56b
P/E (TTM) P/E ratio 28.17
EV/FCF (TTM) EV/FCF 25.15
EV/Sales (TTM) EV/Sales 2.15
P/S ratio (TTM) P/S ratio 1.28
P/B ratio (TTM) P/B ratio 0.87
Revenue growth (TTM) Revenue growth 1.92%
Revenue (TTM) Revenue $4.45b
EBIT (operating result TTM) EBIT $253.00m
Free Cash Flow (TTM) Free Cash Flow $380.00m
Cash position $490.00m
EPS (TTM) EPS $0.41
P/E forward 18.49
P/S forward 1.29
EV/Sales forward 2.16
Short interest 5.40%
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Elanco Animal Health, Inc. forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
60%
Hold
40%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,454 4,454
2% 2%
100%
- Direct Costs 2,553 2,553
6% 6%
57%
1,901 1,901
3% 3%
43%
- Selling and Administrative Expenses 637 637
5% 5%
14%
- Research and Development Expense 342 342
4% 4%
8%
922 922
11% 11%
21%
- Depreciation and Amortization 669 669
3% 3%
15%
EBIT (Operating Income) EBIT 253 253
26% 26%
6%
Net Profit 205 205
118% 118%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
one day ago
GREENFIELD, Ind. , Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025.
Neutral
PRNewsWire
9 days ago
Hunter, Trooper, Scrappy and Buckaroo find zen by using Zenrelia Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) GREENFIELD, Ind., Jan. 27, 2025 /PRNewswire/ -- Scratching, rubbing, chewing, licking.
Positive
Seeking Alpha
21 days ago
Elanco Animal Health is making progress on debt repayment, new product approvals, and launches, despite a 20.5% stock decline since August 2024. The stock drop is mainly due to safety risks with the new drug Zenrelia, requiring additional education for veterinarians, which will slow its launch. ELAN's robust pipeline and strategic acquisitions position it well for future growth, despite current...
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,800
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today